Drug intelligence / Profile preview

COVID-19 vaccine (SET Technology)

Development stage: Preclinical
Lead developer: SET Technology
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics

Overview

COVID-19 vaccine (SET Technology) is a DNA/RNA-based vaccine candidate currently in the optimization phase of development by SET Technology. The vaccine is designed to prevent COVID-19 by utilizing a proprietary platform to deliver genetic material encoding SARS-CoV-2 antigens, thereby stimulating the host's immune system to recognize and neutralize the virus. This candidate is part of SET Technology's broader infectious disease pipeline, which also includes vaccines for Dengue and Andes viruses.

Other names: SET Technology COVID-19 vaccineDNA/RNA-based COVID-19 vaccine

Beyond the preview

Go deeper on COVID-19 vaccine (SET Technology).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVID-19 vaccine (SET Technology).

Explore the full profile